DrugDashboards

Myfortic

mycophenolic acid · MYCOPHENOLATE SODIUM 360 mg/1 · Tablet, Delayed Release · Oral · Novartis Pharmaceuticals Corporation

NDC 00078-0386-66 · 120 TABLET, DELAYED RELEASE in 1 BOTTLE · NDA · View full market →

The short version

18 companies supply this market — deep enough that no single failure threatens the supply. The brand price has held steady around $14.93 per unit over the past year. Generic versions run $0.1720 per unit — 65× cheaper. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$14.93per EAinvoice-surveyed acquisition cost · Jul 8, 2026
  • Medicare Part B pays (ASP+6%)$0.3250per billing unit (180 MG)HCPCS J7518 · Jul 1, 2026
  • Part D plans paid (avg)$10.20per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$14.35per unitnegotiated price across 106 plans — before rebates · Apr 1, 2026
  • Medicaid generic ceiling (FUL)$0.7214per TABweighted avg manufacturer price $0.4122 · Aug 1, 20265% of what pharmacies pay — a deeper discount than 95% of drugs with this benchmark
  • List price (WAC, as filed)$1,581.18per packageNovartis Pharmaceuticals Corporation · Jan 4, 2023

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$14.35per unit
middle half $14.32–$14.55 · 106 plans · Apr 1, 2026
Est. net of rebatesⓘ
$8.61–$10.76
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
2%of plans cover it
tier 4 · prior auth 100% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$5.00$10.00$15.00Jul 2013Sep 2026$14.93
33 price points · per EA · held since Invalid Date · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$448.03
#90 count
$1344.08

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicare Part B (ASP)

Payment limit per 180 MG
$0.325
HCPCS J7518 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$919,377
831 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0● Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for mycophenolic acid (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 4 across plans
  • Costs ≥ $950/fill · avg $1,398.41 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA050791
TE code
AB
Approval date
Feb 27, 2004
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of mycophenolic acid (Tablet, Delayed Release)

LabelerStrengthFirst seenLast seen
Biocon Pharma Inc.MYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 3, 2026
Biocon Pharma Inc.MYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 3, 2026
Major PharmaceuticalsMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.MYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.MYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Advagen Pharma LimitedMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Advagen Pharma LimitedMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Apotex CorpMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Apotex CorpMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Concord Biotech LimitedMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Concord Biotech LimitedMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.MYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.MYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharma Produktions GmbHMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharma Produktions GmbHMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharmaceuticals CorporationMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharmaceuticals CorporationMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Novugen Pharma (USA) LLC.MYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Novugen Pharma (USA) LLC.MYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
PD-Rx Pharmaceuticals, Inc.MYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
PD-Rx Pharmaceuticals, Inc.MYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Remedyrepack Inc.MYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Slate Run Pharmaceuticals, LLCMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Slate Run Pharmaceuticals, LLCMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCMYCOPHENOLATE SODIUM 360 mg/1Jul 15, 2026Aug 31, 2026
Ascend Laboratories, LLCMYCOPHENOLATE SODIUM 180 mg/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Myfortic — NDC 00078-0386-66," retrieved September 3, 2026, https://drugdashboards.com/drug/00078038666.

Free to cite with attribution — see how the data is put together.